SENSEX
NIFTY
GOLD
USD/INR

Weather

image 25    C

Business News

The Economic Times

Business / The Economic Times

details

Symbiotec Pharmalab IPO Day 2: GMP signals 34% upside Should you subscribe?

Symbiotec Pharmalab IPO enters its second day with 80% subscription and a 34% GMP, indicating strong listing expectations. The Rs 1,757 crore issue offers specialised API and biotechnology exposure, while proceeds will reduce debt. However, premium valuations and moderate return ratios warrant careful consideration despite strong investor interest.

25 Aug 2026 9:19 am